Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seclidemstat in advanced solid tumors
NCT03895684Phase 1Completed
- Sponsor
- Salarius Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Seclidemstat in solid tumor (advanced stage), sponsored by Salarius Pharmaceuticals. Primary endpoint: Safety and tolerability of SP-2577 up to 24 months. Started Jun 2019; status: completed.
02
Drugs
Seclidemstat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03895684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895684.